Background
Salix Pharmaceuticals developed Xifaxan, a drug treating irritable bowel syndrome with diarrhea and hepatic encephalopathy. Norwich Pharmaceuticals filed an Abbreviated New Drug Application (ANDA No. 214369) with the FDA to market a generic competitor. Salix sued Norwich in Delaware federal court for patent infringement.
The Delaware District Court held that Norwich’s ANDA infringed Salix’s patents covering hepatic encephalopathy treatment, but that Salix’s patents for irritable bowel syndrome were invalid as obvious. The court entered a final judgment preventing the FDA from approving Norwich’s ANDA No. 214369 until the expiration of Salix’s hepatic-encephalopathy patents in October 2029. The judgment stated: “the effective date of any final approval by the Food and Drug Administration (‘FDA’) of Norwich’s ANDA No. 214369 is to be a date not earlier than the date of expiration of the [hepatic-encephalopathy] Patents.”
After the judgment, Norwich filed an amended ANDA removing the hepatic encephalopathy indication and sought relief from the judgment. The Delaware court denied relief. The FDA subsequently granted only tentative approval, citing the Delaware judgment. Norwich then sued the FDA in D.C. federal court, arguing the FDA misinterpreted the judgment to apply only to the original ANDA, not the amended version.
The Court’s Holding
The D.C. Circuit affirmed, holding that the Delaware District Court’s final judgment applies to Norwich’s ANDA by its specific number (214369), whether amended or not. The court rejected Norwich’s argument that amending the ANDA permitted FDA approval before October 2029. The opinion emphasized that the judgment’s plain language identified the ANDA by number and ordered a delay of “that ANDA’s final approval” without exception for amendments.
The court reinforced this reading through contextual analysis. Before the Delaware judgment, Norwich had explicitly requested language allowing immediate FDA approval of any amended ANDA, which the Delaware court rejected. In Norwich’s subsequent Rule 60(b) motion, Norwich itself repeatedly described the judgment as blocking “FDA’s approval of Norwich’s Amended ANDA,” confirming the judgment applied to the ANDA regardless of amendments. The court also noted that Norwich’s interpretation contradicted the Federal Circuit’s own reading of the Delaware judgment.
The court distinguished Ferring B.V. v. Watson Laboratories, where a district court’s judgment contemplated an amended ANDA because the defendant had promised during trial to amend. Here, Norwich did not make such a commitment during trial and instead attempted post-judgment amendment to circumvent an adverse judgment. The court concluded Norwich could not “litigate a case through trial and final judgment based on a particular ANDA, and then, after final judgment, change the ANDA to what it wishes it had started with, and win in a summary proceeding.”
Key Takeaways
- Final judgments in patent litigation that reference an ANDA by specific number bind that ANDA even if later amended.
- Parties cannot circumvent district court judgments through post-judgment amendments when the judgment’s language does not contemplate such amendments.
- The plain language of a judgment controls its interpretation; courts will not read in implicit exceptions a party explicitly requested and was denied.
- Context, including parties’ briefing and the Federal Circuit’s interpretation, confirms that the judgment applies to the identified ANDA regardless of later modifications.
Why It Matters
This decision has significant implications for the generic pharmaceutical industry and patent litigation strategy. It establishes that generic drug manufacturers cannot escape adverse patent judgments by amending their applications post-judgment. If a district court enters a final judgment blocking FDA approval of a specifically numbered ANDA, that judgment applies to that ANDA in its current form. Companies must decide whether to seek amendments during trial or litigation, not afterward as a workaround.
The ruling also clarifies that courts will not imply qualifications to final judgments when parties explicitly requested such language and were denied. This principle reinforces the importance of clear judgment drafting and discourages strategic post-judgment maneuvering in pharmaceutical patent cases, which frequently involve disputes over ANDA approvals and patent exclusivity periods.